Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $8 on Ironwood Pharmaceuticals; Maintains Sell

Share:
Related IRWD
Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.
Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals (GuruFocus)

Cantor Fitzgerald reiterated its Sell rating on Ironwood Pharmaceuticals, (NASDAQ: IRWD) but raised its price target from $7 to $8 ahead of the Linaclotide PDUFA.

Cantor Fitzgerald said, "We reiterate our SELL rating going into the Linaclotide PDUFA: We remain cautiously optimistic about a first pass approval (we estimate 70% probability) but maintain that the stock is overvalued and could sell off even under a best- case scenario (since investors may play the event and then exit the stock post- approval due to lack of pending positive catalysts)."

Ironwood Pharmaceuticals closed at $12.29 on Friday.

Latest Ratings for IRWD

DateFirmActionFromTo
May 2015Leerink SwannMaintainsMarket Perform
May 2015JP MorganMaintainsOverweight
Apr 2015Bank of AmericaInitiates Coverage onBuy

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (IRWD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters